이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

궤양성 대장염(UC) 성인을 대상으로 토파시티닙과 베돌리주맙을 병용한 연구

2026년 10월 22일 업데이트: Takeda

중등도에서 중증의 활동성 궤양성 대장염 성인 환자를 대상으로 토파시티닙을 이용한 베돌리주맙 이중 표적 요법의 반응 유도 및 완화를 평가하기 위한 오픈 라벨, 제4상, 단일군, 다기관 연구

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with vedolizumab alone after the double treatment.

All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks.

Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

The drugs being tested in this study are called Vedolizumab and Tofacitinib. Vedolizumab and Tofacitinib dual targeted therapy is being tested to treat people with moderate to severe UC who have experienced inadequate response, loss of response or intolerance to no more than 2 prior tumor necrosis factor (TNF) antagonists. This study will look at the clinical remission in people who take Vedolizumab and Tofacitinib dual targeted therapy.

The study will enroll approximately 60 participants. All the participants will be enrolled in a single treatment group to receive dual targeted treatment with Vedolizumab and Tofacitinib for the first 8 weeks:

Vedolizumab 300 mg + Tofacitinib 10 mg

Only those participants who show a clinical response at Week 8 will transition to Vedolizumab monotherapy for 44 weeks.

This multi-center trial will be conducted in the United States and Canada. The overall duration of the study is up to 76 weeks. Participants will be followed up for 26 weeks after the last dose of the study drug for safety.

연구 유형

중재적

등록 (추정된)

60

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Dothan, Alabama, 미국, 36301
        • Digestive Health Specialsits
    • Arizona
      • Sun City, Arizona, 미국, 85351
        • GI Alliance Sun City
    • California
      • Los Angeles, California, 미국, 90048
        • Cedars-Sinai Medical Center
      • Newport Beach, California, 미국, 92663
        • Hoag Hospital Newport Beach
    • Florida
      • Orlando, Florida, 미국, 32803
        • Endoscopic Research Inc
      • Tampa, Florida, 미국, 33615
        • Alliance Clinical Research of Tampa, LLC
    • Georgia
      • Roswell, Georgia, 미국, 30076
        • Gastroenterology Consultants, P.C.
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Medicine
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Medical Center
    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • University of Louisville
    • Louisiana
      • Metairie, Louisiana, 미국, 70006
        • GI Alliance
      • New Orleans, Louisiana, 미국, 70112
        • Tulane University
    • Maryland
      • Chevy Chase, Maryland, 미국, 20815
        • Capital Digestive Care - MGG Group - Chevy Chase Clinical Research
    • Michigan
      • Ypsilanti, Michigan, 미국, 48197
        • Huron Gastroenterology Associates, P.C.
    • Minnesota
      • Plymouth, Minnesota, 미국, 55446
        • MNGI Digestive Health, PA
    • Missouri
      • Kansas City, Missouri, 미국, 64111
        • Mid-America Gastro-Intestinal Consultants
      • Liberty, Missouri, 미국, 64068
        • BVL Clinical Research
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, 미국, 10016
        • NYU Langone Health
      • New York, New York, 미국, 10065
        • Weill Cornell Medical College- New York Presbyterian Hospital
    • North Carolina
      • Asheville, North Carolina, 미국, 28801
        • Digestive Health Partners
      • Chapel Hill, North Carolina, 미국, 27599
        • University of North Carolina
    • Ohio
      • Cincinnati, Ohio, 미국, 45627
        • University of Cincinnati
      • Columbus, Ohio, 미국, 43202
        • Ohio Gastroenterology group, Inc.
      • Westlake, Ohio, 미국, 44145
        • Gastro Intestinal Research Institute of Northern Ohio, LLC.
    • Pennsylvania
      • Wexford, Pennsylvania, 미국, 15090
        • Allegheny Health Network
    • Rhode Island
      • Providence, Rhode Island, 미국, 02094
        • University Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, 미국, 57701
        • Sanford Health Research
    • Texas
      • Houston, Texas, 미국, 77030
        • The University of Texas Health Science Center at Houston
      • Mansfield, Texas, 미국, 76063
        • GI Alliance - Mansfield
      • San Antonio, Texas, 미국, 78229
        • Gastroenterology Research of San Antonio, LLC
      • Southlake, Texas, 미국, 76092
        • Texas Digestive Disease Consultants (TDDC), Southlake
      • Tyler, Texas, 미국, 75701
        • Tyler Research Institute, LLC
      • Webster, Texas, 미국, 77598
        • GI Alliance - Webster
    • Utah
      • Salt Lake City, Utah, 미국, 84108
        • University of Utah Health
    • Washington
      • Tacoma, Washington, 미국, 98405
        • Washington Gastroenterology- GIA
    • Ontario
      • Barrie, Ontario, 캐나다, L4M 7G1
        • Barrie GI Associates Inc.
      • London, Ontario, 캐나다, N6A 5A5
        • London Health Sciences Centre
      • Mississauga, Ontario, 캐나다, L5M 7N4
        • West GTA Endoscopy Inc.
      • North Bay, Ontario, 캐나다, P1B 2H3
        • Viable Clinical Research - North Bay
      • North York, Ontario, 캐나다, M6A3B4
        • Toronto Immune and Digestive Health Institute Inc. (TIDHI)
      • Oakville, Ontario, 캐나다, L6L 5L7
        • ABP Research Services Corp.
      • Oshawa, Ontario, 캐나다, L1J 0C7
        • Taunton Surgical Centre
      • Vaughan, Ontario, 캐나다, L4L 4Y7
        • Toronto Digestive Disease Associates (TDDA) Inc.
    • Quebec
      • Montreal, Quebec, 캐나다, H3G 1A4
        • The Research Institute of the McGill University Health Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Has a confirmed diagnosis of UC established at least 3 months prior to screening, by clinical and endoscopic evidence and corroborated by a histopathology report.
  2. Has moderately to severely active UC as determined by a complete Mayo score [including PGA] of 6 to 12 with a rectal bleeding subscore ≥1 and a centrally assessed endoscopic subscore ≥2 at screening.
  3. Has evidence of UC extending proximally to the rectum [≥15 centimeter (cm) of involved colon].
  4. Participants with extensive colitis or pancolitis of >8 years duration or left sided colitis >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit.
  5. Participants with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factors must be up to date on colorectal cancer surveillance.
  6. Has demonstrated an inadequate response to, loss of response to, or intolerance to at least 1, but no more than 2 TNFα antagonists. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued TNFα antagonist therapy for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the medical monitor.

Note: After the interim analysis, participants with inadequate response, loss of response, or intolerance to conventional UC therapy per standard of care treatment without prior exposure to biologics may be enrolled if deemed appropriate. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued biologics for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the Medical Monitor. If using corticosteroids must be on a stable dose of oral corticosteroids up to a maximum of 40 mg daily of prednisone or 9 mg daily of budesonide, or equivalent for at least 2 weeks prior to screening endoscopy and must be willing to follow a mandatory taper of corticosteroids.

Exclusion Criteria:

Gastrointestinal Exclusion criteria:

  1. Has any of the following UC-related complications:

    1. Acute severe UC.
    2. The participant has had extensive colonic resection, subtotal or total colectomy.
    3. The participant has clinical evidence of abdominal abscess or toxic megacolon.
    4. The participant has an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
    5. Short bowel syndrome.
  2. Has Crohn's colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug (NSAID) induced colitis, idiopathic colitis (i.e, colitis not consistent with UC), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption. Participants with a history of colonic mucosal dysplasia are also excluded.

  3. Has uncontrolled primary sclerosing cholangitis.

Infectious Disease Exclusion Criteria:

  1. Has any evidence of an active systemic infection during screening. Participants with nonsystemic infections (eg, active fungal infection of nail beds) may be eligible, if in the opinion of the investigator, inclusion of the participant will not interfere with the collection or interpretation of study results and poses no risk to the participant.

  2. Has active or latent tuberculosis (TB), regardless of treatment history, as evidenced by any of the following:

    1. History of TB.
    2. A diagnostic TB test performed during screening that is positive, as defined by:

    i. A positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests or ii. A tuberculin skin test reaction ≥10 mm (≥5 mm in participants receiving the equivalent of >15 mg daily prednisone).

  3. A positive test for hepatitis B virus (HBV).

  4. A positive test for hepatitis C virus (HCV).

  5. Evidence of, or treatment for, Clostridium difficile infection or other intestinal pathogen during screening. Participants who test positive for C. difficile or other intestinal pathogens at screening and receive treatment may be enrolled or rescreened (if required) following confirmation of infection resolution.

  6. Evidence of active Cytomegalovirus (CMV) infection at screening.

Medication exclusion criteria:

  1. Has received immunomodulators (eg, 6-mercaptopurine, azathioprine, and methotrexate) within 4 weeks prior to first dose or immunosuppressants (eg, cyclosporine, tacrolimus) within 8 weeks prior to first dose.

  2. Any medicinal product, herbal medication, or natural health product which might interfere with cytochrome P450 genotype 3A4 (CYP3A4) within 2 weeks prior to enrollment, except for any CYP3A4 modulator used to treat a C. difficile or an intestinal pathogen infection at screening.

  3. Has received any of the following medical therapies for UC:

    1. IV antibiotics within 8 weeks prior to enrollment.
    2. Any rectal therapy for treatment of UC within 2 weeks prior to screening endoscopy.
    3. Chronic NSAID use defined as daily use for >2 consecutive weeks (Note: occasional use [<2 consecutive weeks] of NSAIDs and acetaminophen [<100 mg daily] for headache, arthritis, myalgias, or menstrual cramps and chronic low dose aspirin use [81-162.5 mg daily] for cardiovascular prophylaxis are permitted).
  4. Has received a live vaccine within 4 weeks prior to first dose.

General Exclusion Criteria:

  1. Has any of the following cardiovascular or thrombotic conditions:

    1. Recent (within past 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting.
    2. Recent (within past 6 months) moderate to severe congestive heart failure (New York Heart Association class III or IV).
    3. Prior history of thrombotic events, including deep vein thrombosis and pulmonary embolism.
    4. Known inherited conditions that predispose to hypercoagulability.
  2. History of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.

  3. A surgical procedure requiring general anesthesia within 3 months prior to screening or is planning to undergo major surgery during the study period.

  4. Any investigational procedure ≤4 weeks prior to screening that, in the investigator's opinion, may interfere with interpretation of study results.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Vedolizumab 300 mg + Tofacitinib 10 mg

Participants will receive Vedolizumab 300 mg, intravenous (IV) infusion, at Week 0, Week 2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to Week 8. Participants with clinical response at Week 8 will transition to receive vedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46.

Vedolizumab IV infusions

다른 이름들:
  • 엔티비오
  • MLN0002

Tofacitinib Tablets

다른 이름들:
  • 젤잔즈
  • CP-690
  • CP-550

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score
기간: At Week 8

Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a Physician's Global Index (PGA) and Mayo endoscopic findings (MES). Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants Achieving Clinical Remission at Week 52 Based on Complete Mayo Score
기간: At Week 52

Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants Achieving Clinical Remission at Weeks 8, 14, and 26 Based on Partial Mayo Score
기간: At Weeks 8, 14 and 26

Clinical remission based on complete Mayo Score is where a participant achieves partial Mayo Score ≤2 points with no individual subscore >1. Partial Mayo Score consists of 3 variables of the Mayo Clinic Score: stool frequency, rectal bleeding and PGA. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity.

At Weeks 8, 14 and 26
Percentage of Participants Achieving Clinical Response at Weeks 2, 6, 8, 14, 26 and 52 Based on Complete or Partial Mayo Score
기간: At Weeks 2, 6, 8, 14, 26, and 52

Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline or a partial Mayo score of ≥2 points and ≥25% from baseline, if the complete Mayo score was not performed at the visit with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Weeks 2, 6, 8, 14, 26, and 52
Percentage of Participants Achieving Clinical Remission at Week 8 and Week 52 Based on Modified Mayo Score
기간: At Weeks 8 and 52

Clinical remission based on modified Mayo Score is where a participant achieves component modified Mayo score of ≤2 with modified MES ≤1, rectal bleeding = 0, and stool frequency ≤1. Modified Mayo Score consists of 3 variables: stool frequency, rectal bleeding and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity.

At Weeks 8 and 52
Percentage of Participants With Endoscopic Improvement at Week 8 and Week 52 Based on Modified Mayo Endoscopic Subscore (MMES)
기간: At Weeks 8 and 52

Endoscopic improvement based on modified mayo endoscopic score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease.

At Weeks 8 and 52
Percentage of Participants With Durable Clinical Remission at Week 8 and Week 52
기간: At Week 8 and Week 52

Durable clinical remission is defined as the clinical remission at Week 8 and Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Weeks 8 and 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8 and Week 52
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 8
기간: At Week 8

Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 8
기간: At Week 8

Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 8. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 52
기간: At Week 52

Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 52
기간: At Week 52

Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 52, and was off corticosteroids at least 3 months prior to Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 52
Percentage of Participants Achieving Clinical Response at Week 8
기간: At Week 8

Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity.

At Week 8
Percentage of Participants With Endoscopic Improvement at Week 52
기간: At Week 52

Endoscopic improvement based on modified mayo score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease.

At Week 52
Percentage of Participants With Histological Remission Based on Geboes Score at Week 52
기간: At Week 52

Histological remission is defined as Geboes score <2 at Week 52. The Geboes score is a histological grading system for assessing histological disease activity in UC. The Geboes score evaluates 7 histological features. It consists of 6 grades (0-6). Each of the grades is divided into subgrades, based on the severity of tissue abnormalities or the extent of inflammatory cell infiltration. The Geboes score ranges from 0.0 to 5.4, and higher grades are indicative of more severe disease activity.

At Week 52
Change in C-Reactive Protein Levels (CRP) From Baseline
기간: Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52

CRP is a useful marker of inflammation in participants with inflammatory bowel disease (IBD). In participants with UC, elevated CRP has been associated with severe clinical activity.

Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
Change in Fecal Calprotectin Concentrations From Baseline
기간: Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52

Fecal calprotectin is a biomarker for intestinal inflammatory activity.

Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline
기간: At Weeks 8, 26 and 52

The IBDQ is an instrument used to assess quality of life in adult participants with inflammatory bowel disease (IBD). It includes 32 questions on 4 domains of Health-Related Quality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic Function (5 items). Participants are asked to recall symptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert scale (1=worst to 7=best). A total IBDQ score is calculated by summing the scores from each domain; the total IBDQ score ranges from 32 to 224, with lower scores reflecting worse HRQOL. A positive change from Baseline indicates improvement.

At Weeks 8, 26 and 52
Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline
기간: At Weeks 8, 26 and 52

The FACIT-F is a validated, 13-item questionnaire to assess fatigue in participants with a variety of chronic illnesses, including participants with IBD. Items are rated on a 5-point Likert scale and the total score ranges from 0 to 52 with lower scores representing greater fatigue.

At Weeks 8, 26 and 52
Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
기간: Up to 76 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention.

Up to 76 weeks
Number of Participants With Clinically Significant Change in Vital Signs From Baseline
기간: Up to 76 weeks

Vital signs will include body temperature, respiratory rate, blood pressure (resting more than 5 minutes), and pulse (resting more than 5 minutes).

Up to 76 weeks
Number of Participants With Clinically Significant Physical Examination Findings
기간: At Baseline and From Week 14 to Week 72

A baseline physical examination (defined as the assessment before first dose of study medication) will consist of the following body systems: general appearance; HEENT (head, eyes, ears, nose, and throat); cardiovascular system; respiratory system; gastrointestinal system; dermatologic system; extremities; musculoskeletal system; nervous system; lymph nodes; and other. All subsequent physical examinations will assess clinically significant changes from the assessment prior to first dose examination.

At Baseline and From Week 14 to Week 72
Number of Participants With Markedly Abnormal Laboratory Values
기간: Up to 76 weeks

Standard laboratory tests will include clinical chemistry, hematology, coagulation and urinalysis.

Up to 76 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Study Director, Takeda

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 6월 12일

기본 완료 (추정된)

2027년 7월 9일

연구 완료 (추정된)

2027년 7월 9일

연구 등록 날짜

최초 제출

2023년 10월 18일

QC 기준을 충족하는 최초 제출

2023년 10월 18일

처음 게시됨 (실제)

2023년 10월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 26일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 22일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD 공유 액세스 기준

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다